Investor Overview

Corporate Profile


Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket’s multi-platform development approach applies the well-established lentiviral virus, which we refer to as LVV, adeno-associated virus, which we refer to as AAV, gene therapy platforms.

Stock Information

NASDAQ | RCKT (Common Stock)

$14.97

 0.03 (0.20%)

High$15.30
Low$14.97
Volume12,706
Market Cap$673,286,130

February 20, 2019  10:54 a.m. ET

Minimum 15 minute delay, Data provided by Nasdaq

Stock chart for: RCKT.O.  Currently trading at $14.97 with a 52 week high of $25.96 and a 52 week low of $10.75.